Galactomannan detection from piperacillin-tazobactam brands available in the brazilian market

• Autor(a) principal: Xavier, Melissa Orzechowski
• Data de Publicação: 2009
• Outros Autores: Pasqualotto, Alessandro Comarú, Aquino, Valério Rodrigues, SukiennikI, Teresa Cristina Teixeira, Severo, Luiz Carlos
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Institucional da FURG (RI FURG)
• Texto Completo: http://repositorio.furg.br/handle/1/2618; http://dx.doi.org/10.1590/S1413-86702009000500007
• topic: Piperacillin-tazobactam; Aspergillosis; Platelia aspergillus; Galactomannan

Piperacillin-tazobactam is a broad spectrum antimicrobial agent that can cause false-positive results in the commercial Platelia Aspergillus EIA test. So far, no study has been performed in Latin America to evaluate the clinical implication of this finding. Here we studied the potential for galactomannan detection in piperacillintazobactam batches commercialized in the Brazilian market. Five batches from distinct laboratories were tested in duplicate in the Platelia Aspergillus EIA according to the manufacturer’s instructions. Only one drug showed crossreaction at a cut-off of 0.5. Human serum was spiked with this particular drug aiming to mimic achievable piperacillintazobactam concentrations in the serum. Results were all negative for galactomannan detection, even at high drug concentrations. Results from this pilot study suggest that piperacillin-tazobactam might not be a clinically significant cause of false-positive results in the Platelia Aspergillus EIA test in Brazil.